FDA approves bevacizumab biosimilar ‘bevacizumab-tnjn’ for lung and colorectal cancer
Credit: U.S. Food and Drug Administration The U.S. Food and Drug Administration (FDA) has approved Bio-Thera Solutions’ bevacizumab (Avastin) biosimilar, bevacizumab-tnjn (Avzivi), for the treatment of lung and colorectal cancer.1 The decision marks Bio-Thera Solutions’ second FDA-approved product in the United States. The decision, announced on December 7, 2023, was based on both clinical and […]
FDA approves Fluzakura for treatment of refractory metastatic colorectal cancer
November 9, 2023 2 minute read Add topics to email alerts Receive an email when a new article is posted Enter your email address to receive emails when new articles are posted. . ” data-action=”subscribe”> Subscribe Your request could not be processed. Please try again later. If you continue to experience […]
Takeda Pharmaceutical Announces FDA Approval of Colorectal Cancer Treatment
Pharmaceutical company Takeda JP:4502 announced Wednesday that the U.S. Food and Drug Administration has approved Fluzakura for the treatment of certain colorectal cancer patients. Fluzacra (fruquintinib), an oral targeted therapy, has been approved for adults with metastatic colorectal cancer who have received certain prior treatments. of…
FDA approves Fluzakura for previously treated metastatic colorectal cancer
The Food and Drug Administration (FDA) has approved Fluzakura (fruquintinib) for the treatment of some adults with metastatic colorectal cancer (mCRC), biopharmaceutical company Takeda Pharmaceutical announced in a news release. Patients are eligible for treatment with Fluzacra, an oral targeted therapy, after treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy and anti-VEGF therapy. Patients with wild-type RAS […]
Takeda receives FDA approval for fruquintinib for certain colorectal cancer patients
Photo: Takeda sign outside the California office/iStock; JHVE Photo The FDA on Wednesday approved Takeda Pharmaceutical’s fruquintinib for adult patients with previously treated metastatic colorectal cancer. Oral targeted therapy for VEGF-1, -2, and -3 receptors carries the brand name Furuzakura. Full Sakura-san label Patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan chemotherapy, and anti-VEGF agents are […]
FDA approves fruquintinib for metastatic colorectal cancer
Approved by the US Food and Drug Administration fruquintinib (Furuzakura, Takeda) Treatment for certain metastatic adults colorectal cancer People who have experienced disease progression during or after previous treatment. More specifically, this approval also extends to adult patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy, anti-VEGF therapy, and in […]
FDA approves fruquintinib for metastatic colorectal cancer
The FDA has approved fruquintinib (Fluzacra) for the treatment of adult patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, or anti-VEGF therapy. R.A.S. Wild-type, medically relevant anti-EGFR therapy.1 This approval was based on results from the multiregional phase 3 FRESCO-2 trial (NCT04322539) and the Chinese phase 3 FRESCO trial […]